Edition:
India

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

3.95USD
9:14pm IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.95
Open
$4.04
Day's High
$4.04
Day's Low
$3.95
Volume
3,385
Avg. Vol
102,138
52-wk High
$22.16
52-wk Low
$3.21

Select another date:

Sat, Dec 9 2017

BRIEF-Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful

* AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT

BRIEF-Akari Therapeutics proposes public offering of ADS

* Akari Therapeutics announces proposed public offering of American Depositary Shares Source text for Eikon: Further company coverage:

BRIEF-Akari Therapeutics announces further clinical progress

* Akari Therapeutics - 3 additional patients have been enrolled in ongoing Phase II Cobalt clinical trial of Coversin in patients with PNH​

BRIEF-Akari ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

* ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

BRIEF-Akari Therapeutics appoints David Horn Solomon as CEO

* Akari Therapeutics announces appointment of David Horn Solomon as CEO

BRIEF-Akari Therapeutics PLC files for mixed shelf of up to $100 mln

* Akari Therapeutics PLC files for mixed shelf of up to $100 million – SEC filing Source text: (http://bit.ly/2vLqRqG) Further company coverage:

Select another date: